Prolactin levels and adverse events in patients treated with risperidone

Journal of Clinical Psychopharmacology

Volumn 19, Issue 1, 1999, Pages 57-61

  Kleinberg, David L ^a   Davis, John M ^b   De Coster, Roland ^c   Van Baelen, Bart ^c   Brecher, Martin ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PROLACTIN; RISPERIDONE;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEMALE SEXUAL DYSFUNCTION; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SEX DIFFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GALACTORRHEA; HUMANS; MALE; PROLACTIN; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 0032952480     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199902000-00011     Document Type: Article

References (21)

1. Kebabian JW, Caine DB. Multiple receptors for dopamine. Nature 1979;277:93-6.
2. Kleinberg DL, Noel GL, Frantz AG. Chlorpromazine stimulation and L-dopa suppression of prolactin. J Clin Endocrinol Metab 1971;33:873-6.
3. Sachar EJ, Gruen PH, Altman N, et al. Use of neuroendocrine techniques in psychopharmacological research. In: Sachar EJ, ed Hormones, behavior, and psychopathology. New York. Raven Press, 1976:161-16.
4. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
5. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of rispendone and halperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1992;13:25-40.
6. Madder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
7. Peuskens J, and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational multi center, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
8. Beasley CM Jr, Tollefsen G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
9. Brecher M, Lemmens P, Van Baelen B. Tolerability and cardiovascular safety of risperidone. Poster presented at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-13, 1996.
10. Dickson RA, Dalby JT, Williams R, Edwards AL. Rispendone-induced prolactin elevations in premenopausal women with schizophrenia [letter]. Am J Psychiatry 1995;152:1102-3.
11. Scandinavian Society of Psychopharmacology Committee of Clinical Investigation (UKU). The UKU side effect rating scale scale for the registration of unwanted effects of psychotropics. Acta Psychiatr Scand Suppl 1987;334:81-94.
12. Bowden CR Voina SJ, Woestenborghs R, De Coster R, Heykants J. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J Pharmacol Exp Ther 1992;26:699-706.
13. Thorner MO, Vance ML, Horvath E, Kovacs K. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. Philadelphia: WB Saunders Company, 1992;221-310.
14. Biller BMK, Baum HBA, Rosenthal DI, Saxe VC, Charpie PM Klibanski A. Progressive trabecular osteopema m women with hyperprolactinemic amenorrhea. J Clin Endocnnol Metab 1982; 75:692-7.
15. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
16. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, veldhuis, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996;81:3654-62.
17. Siever LJ. The effects of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. J Clin Psychopharmacol 1981;1:2-7.
18. Koenig K, Toniolo P, Bruning P, Bonfrer J, Shore R, Zeleniuch-Jacquotte A, Pasternack B. Prospective study of serum prolactin and breast cancer [letter]. Am J Epidemiology 1993;138:601.
19. Kewitz H, Zesdinsky HJ, Schroter PM, Lindter E. Reserpine and breast cancer in women in Germany. Eur J Clin Pharmacol 1977;11:79-83.
20. Shapio S, Parsells JL, Rosenberg L, Kaufman DW Stolley PD, Schottenfeld D. Risk of breast cancer in relation to the use of Rauwolfia alkaloids. Eur J Clin Pharmacol 1984;26:143-6.
21. Goode DJ, Corbett WJ, Schey HM, Suh SH, Woodie B, Morris DL, Mousey L. Breast cancer in hospitalized psychiatric patients. Am J Psychiatry 1981;138:804-6.